About
Biorithm's flagship product, femom, is a comprehensive maternity care platform designed to bridge the gap between clinic visits during pregnancy. It combines a clinical-grade fetal-maternal monitor with a mobile patient app, connected point-of-care devices (such as blood pressure monitors and glucometers), and a clinician-facing dashboard to deliver true continuity of care anytime, anywhere. The femom fetal-maternal monitor uses electrophysiological signals to non-invasively record fetal heart rate, maternal heart rate, and uterine contractions from a single position in a single measurement, converting the data into a CTG trace for easy review by clinical teams. The platform supports home spot-checks, scheduled virtual visits, and real-time symptom reporting, giving clinicians trending health information and clinical decision support tools to identify early signs of complications. femom is particularly suited for managing complex conditions such as hypertensive disorders, gestational diabetes (GDM), and other multi-condition pregnancies. The platform enriches the mother-clinician relationship by providing personalised, data-driven care plans while actively engaging patients in their own healthcare journey. Biorithm is a MedTech startup spun off from Nanyang Technological University with offices in Cambridge, Massachusetts and Singapore. The device is currently in the clinical investigation phase and is not yet FDA-cleared. It is targeted at healthcare providers, obstetric practices, and hospital systems seeking to modernise and extend maternity care beyond the clinic.
Key Features
- Clinical-Grade Fetal-Maternal Monitor: Non-invasive electrophysiological monitor captures fetal heart rate, maternal heart rate, and uterine contractions from a single position, converting data to a CTG trace for clinician review.
- Remote Patient Monitoring App: The femom app allows expectant mothers to perform home spot-checks, report symptoms, and participate in scheduled virtual visits, keeping them connected to their care team between appointments.
- Clinician Dashboard & Clinical Decision Support: A web-based provider dashboard aggregates trending health data, risk indicators, and patient-reported outcomes to help clinicians take timely, data-driven interventions.
- Connected Point-of-Care Device Integration: Integrates with external devices such as BP monitors and glucometers to capture a comprehensive picture of maternal health alongside biometric sensor data.
- Personalised Care Plans: Supports management of simple and complex pregnancies including hypertensive disorders and gestational diabetes, with tailored care plans for individual patient needs.
Use Cases
- Remote monitoring of high-risk pregnancies with conditions such as hypertension or gestational diabetes, enabling clinicians to track trends and intervene early.
- Routine prenatal care augmentation, allowing low-risk expectant mothers to perform home spot-checks between scheduled clinic appointments.
- Virtual obstetric consultations supported by real-time biometric data, enabling clinicians to conduct data-informed telehealth visits.
- Hospital and obstetric practice workflows seeking to reduce unnecessary in-person visits while maintaining clinical oversight of patient health.
- Clinical research and investigation into fetal-maternal electrophysiological monitoring for improving pregnancy outcome measurement and prediction.
Pros
- Continuous Care Between Clinic Visits: Enables real-time monitoring and symptom tracking throughout pregnancy, closing the gap during the 99% of time patients are outside the clinic.
- Multi-Biometric Single-Session Measurement: Captures multiple clinically relevant signals in one non-invasive measurement session, reducing burden on both patients and care staff.
- Designed with Clinicians and Patients: Developed in collaboration with women, clinicians, and university hospitals, ensuring the platform addresses real-world obstetric and patient needs.
Cons
- Not Yet FDA-Cleared: The fetal-maternal monitor is currently in the clinical investigation phase and has not received FDA clearance, limiting availability in certain markets.
- Enterprise-Focused with No Self-Service Option: The platform is designed for healthcare providers and institutions rather than individual consumers, requiring clinical onboarding and integration.
- Limited Public Pricing Transparency: Pricing and deployment details are not publicly available and require direct contact with the Biorithm sales team.
Frequently Asked Questions
What is femom?
femom is Biorithm's comprehensive obstetric remote monitoring solution. It includes a clinical-grade fetal-maternal monitor, a patient mobile app, connected point-of-care devices, and a clinician dashboard to support continuous, data-driven pregnancy care.
How does the femom fetal-maternal monitor work?
The monitor uses electrophysiological signals to non-invasively record fetal heart rate, maternal heart rate, and uterine contractions from a single body position in a single measurement session. The data is then converted into a CTG trace for easy review by the clinical team.
Is the femom device FDA-cleared?
No, the femom fetal-maternal monitor is not yet FDA-cleared. It is currently in the clinical investigation phase.
Who is femom designed for?
femom is designed for healthcare providers, obstetric practices, and hospital systems that want to extend maternity care beyond the clinic. It supports management of both routine and high-risk pregnancies, including conditions like hypertensive disorders and gestational diabetes.
Where is Biorithm based?
Biorithm has offices in Cambridge, Massachusetts (USA) and Singapore. The company was spun off from Nanyang Technological University in Singapore and was founded by doctors and engineers.
